Genentech Oncology
CD20 is a transmembrane protein and B-cell surface marker that is involved in the development and differentiation of B cells.1 CD20 is expressed in a majority of B-cell malignancies, including chronic lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma.1,2
CD3 is a multimeric protein composed of 4 subunits (γ, δ, ε, ζ), which are part of the T-cell receptor (TCR) complex on the surface of T cells. Engagement of CD3 induces downstream signaling events that result in T-cell activation.3
Binding CD20 on B cells and CD3 on T cells can engage T cells and redirect their activity against B cells. T-cell activation—a result of the CD20-CD3 interaction—promotes the proliferation/expansion of pre-existing T cells, which may further contribute to the depletion of B cells.4-5
Naeim F, Rao PN, Song SX, Grody WW. Principles of immunophenotyping. In: Atlas of Hematopathology: Morphology, Immunophenotype, Cytogenetics, and Molecular Approaches. London, UK: Academic Press; 2013:25-46.
Naeim F, Rao PN, Song SX, Grody WW. Principles of immunophenotyping. In: Atlas of Hematopathology: Morphology, Immunophenotype, Cytogenetics, and Molecular Approaches. London, UK: Academic Press; 2013:25-46.
Prevodnik VK, Lavrenčak J, Horvat M, Novakovič BJ. Diagn Pathol. 2011;6:33. PMID: 21486448
Prevodnik VK, Lavrenčak J, Horvat M, Novakovič BJ. Diagn Pathol. 2011;6:33. PMID: 21486448
Davis MM. Cell. 2002;110:285-287. PMID: 12176315
Davis MM. Cell. 2002;110:285-287. PMID: 12176315
Bacac M, Klein C, Umana P. Oncoimmunology. 2016;5:e1203498. PMID: 27622073
Bacac M, Klein C, Umana P. Oncoimmunology. 2016;5:e1203498. PMID: 27622073
Sun LL, Ellerman D, Mathieu M, et al. Sci Transl Med. 2015;7:287ra70. PMID: 25972002
Sun LL, Ellerman D, Mathieu M, et al. Sci Transl Med. 2015;7:287ra70. PMID: 25972002
Discover our broad range of antitumor modalities.
Learn more about the importance of cancer biomarkers.
The compounds and their uses mentioned on this website are investigational and have not been approved by the US Food and Drug Administration. Efficacy and safety have not been established. The information presented should not be construed as a recommendation for use. Do you wish to proceed?
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.